SACHS BRUCE I 4

What Happened Bruce I. Sachs, a director of Vertex Pharmaceuticals (VRTX), received an award of 107.345 deferred stock units on April 15, 2026. The units are valued at $442.50 each for a total reported value of $47,500. Transaction code A indicates an award/acquisition; these are derivative units rather than an open-market purchase.

Key Details

• Transaction date: 2026-04-15; Form 4 filed: 2026-04-17 (filed timely within SEC 2-business-day requirement).
• Units awarded: 107.345 deferred stock units at $442.50 per share; total reported value $47,500.
• Shares owned following transaction: not shown in the provided excerpt of the filing.
• Footnote (F1): Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest of (i) termination of Mr. Sachs' board service, (ii) a change of control, or (iii) Mr. Sachs' disability or death.
• Nature of transaction: derivative award (deferred stock units), not an immediate equity purchase or sale.

Context Deferred stock units are a form of director compensation that convert to actual shares only upon specified payout events; they do not represent immediate market buying or selling. Such grants are routine for non-employee directors and should be viewed as compensation rather than a direct signal of insider sentiment.